Quercetin inhibits lymphocyte activation and proliferation without inducing apoptosis in peripheral mononuclear cells

Leuk Res. 2009 Jan;33(1):140-50. doi: 10.1016/j.leukres.2008.07.025. Epub 2008 Sep 5.

Abstract

Toxicity of chemotherapeutic drugs towards normal cells is a serious side effect of cancer treatment. Thus, finding of molecules with low toxicity for normal cells is crucial. Several natural compounds, such as flavonoid quercertin, are receiving a growing attention as "chemopreventers". Quercetin kills tumour-derived cell lines, but little is known about its effects on normal cells. Here we show that although quercetin exerts a higher apoptotic potential on leukemic cell lines than on peripheral blood mononuclear cells (PBMCs) and does not sensitize PBMCs to CD95-induced apoptosis, it is able to inhibit normal immune functions such as T cell proliferation and activation. Quercetin sensitivity is independent on cell cycle progression since it was not abrogated in serum-starved U937 cells, nor proliferating PBMCs underwent apoptosis after quercetin treatment. However, quercetin prevented PHA-induced PBMC proliferation and SEB-induced upregulation of activation markers. Our data suggest that quercetin, while incapable of inducing apoptosis in normal cells under several conditions, could interfere with effector T cell function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Cell Proliferation / drug effects*
  • Flow Cytometry
  • Humans
  • Immunophenotyping
  • Lymphocyte Activation / drug effects*
  • Quercetin / pharmacology*
  • U937 Cells

Substances

  • Quercetin